Oncopathology Research Center.
Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine.
Cancer Biomark. 2018;21(4):821-837. doi: 10.3233/CBM-170755.
CD105 is recently described as a cancer stem cell (CSC) marker.
The present study was aimed to investigate the expression and prognostic significance of the CSC marker CD105 in different histological subtypes of renal cell carcinoma (RCC).
Expression of CD105 was evaluated using immunohistochemistry in RCC samples on tissue microarrays including clear cell RCCs (ccRCCs), papillary, and chromophobe RCCs. The association between CD105 expression and clinicopathological features as well as survival outcomes was determined.
In ccRCC, increased tumoral cytoplasmic and endothelial expression of CD105 were significantly associated with advanced stage, renal vein invasion, and microvascular invasion (MVI). In addition, MVI was associated with a worse overall survival (OS). Moreover, in multivariate analysis tumor stage and nuclear grade were independent prognostic factors for OS both in case of tumoral cytoplasmic and endothelial CD105 expression. Additionally, CD105 expression was found to be a predictor of worse OS in univariate analysis. However, in papillary and chromophobe RCC, no significant association was found between CD105 expression and clinicopathological parameters or prognosis.
We showed that CD105 expression was associated with more aggressive tumor behavior, more advanced disease, and worse prognosis in ccRCC but not in the other RCC subtypes.
CD105 最近被描述为癌症干细胞（CSC）标志物。
本研究旨在探讨 CSC 标志物 CD105 在不同组织学亚型肾细胞癌（RCC）中的表达及其预后意义。
采用免疫组织化学法在组织微阵列上检测 RCC 样本中 CD105 的表达，包括透明细胞 RCC（ccRCC）、乳头状和嫌色细胞 RCC。确定 CD105 表达与临床病理特征和生存结果之间的关联。
在 ccRCC 中，肿瘤细胞质和内皮 CD105 的表达增加与晚期、肾静脉侵犯和微血管侵犯（MVI）显著相关。此外，MVI 与总生存期（OS）更差相关。此外，在多变量分析中，肿瘤分期和核分级是 OS 的独立预后因素，无论是肿瘤细胞质还是内皮 CD105 表达。此外，CD105 表达在单变量分析中是 OS 较差的预测指标。然而，在乳头状和嫌色细胞 RCC 中，CD105 表达与临床病理参数或预后之间没有显著关联。
我们表明，CD105 表达与 ccRCC 中更具侵袭性的肿瘤行为、更晚期的疾病和更差的预后相关，但与其他 RCC 亚型无关。
